Tyra Biosciences stock tumbles 30% on phase 2 trial results

Tyra Biosciences shares fell 30% after initial Phase 2 SURF302 data for dabogratinib, despite a reported 79% overall response rate and 64% complete response rate at the 60 mg once-daily dose in combined evaluable patients. The 60 mg cohort showed a 100% overall response rate and 75% complete response rate in single-marker-lesion patients, with no Grade 4 or 5 treatment-emergent adverse events and no treatment-related discontinuations at that dose. Tyra plans to complete 60 mg enrollment, begin a 70 mg cohort, and consult regulators on Phase 3 design and dose selection.

Analysis

The selloff likely reflects an expectations reset rather than a clean clinical failure: the efficacy read is based on a denominator too small to establish response durability, dose-response, or reproducibility across lesion burden. For TYRA, the next valuation driver is not another best-response datapoint but the 6- and 12-month complete-response durability, recurrence-free interval, and discontinuation profile needed to support a registrational design. Until those are visible, Phase 3 timing, required sample size, and cash runway remain the dominant multiple risks over the next 6-18 months.

A credible oral FGFR3 option with durable activity would pressure localized urothelial-care franchises by shifting treatment earlier in the pathway, with the clearest longer-term read-through to UroGen (URGN) in low-grade upper-tract disease and, more indirectly, intravesical NMIBC developers such as CG Oncology (CGON). The contrarian view is that the initial price reaction may be excessive if the market is penalizing an early dataset despite tolerability that permits sustained dosing; however, that only becomes investable after the next update establishes durability without liver, ocular, or phosphate-related attrition. The key near-term risk is that dose escalation produces incremental toxicity without meaningfully improving durable CR, forcing a less favorable Phase 3 dose and materially increasing development cost and time to market.

Key Decisions for Investors

• Do not add directional TYRA exposure on the initial move; set a watch alert for protocol-level disclosure of the Phase 3 endpoint, durability requirement, enrollment size, and expected start date. A favorable regulatory alignment is a 1-3 month upside catalyst, while a delayed or randomized registrational path would justify further downside.
• For existing TYRA holders, retain only a reduced event position sized for binary clinical risk and use any rebound before the next durability update to reduce exposure. Thesis is falsified if the selected dose shows meaningful treatment discontinuations or if landmark complete-response durability materially trails the level required to displace procedural therapy.
• Monitor URGN as the cleaner competitive read-through: if TYRA reports durable upper-tract responses in a larger cohort, reassess URGN's long-term terminal-value assumptions rather than its near-term revenue. This is a 6-18 month risk, not an immediate revenue threat, given development and approval timelines.
• Avoid a TYRA/CGON pair trade at present: the products target overlapping but non-identical settings, and relative performance will be driven by durability, regulatory positioning, and commercial sequencing that are not yet disclosed. Revisit after TYRA provides landmark efficacy and the registrational design.